Anticonvulsants for the treatment of alcohol withdrawal syndrome and alcohol use disorders.

abstract：:A number of news items and case reports describing complex behaviours (e.g. sleep driving, sleep cooking, sleep eating, sleep conversations, sleep sex) associated with the use of hypnosedative medications have recently received considerable attention. Regulatory agencies examining these reports have subsequently issue...

journal_title：CNS drugs

authors： Dolder CR,Nelson MH

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND:There is growing epidemiological evidence that opioids may increase the risk of unintentional injuries and it is plausible that the time of initiation is most critical in that respect. Studies on fall-related injuries remain few, limited and mostly focused on specific groups of elderly patients. OBJECTIVE:T...

journal_title：CNS drugs

authors： Söderberg KC,Laflamme L,Möller J

更新日期：2013-02-01 00:00:00

abstract：:At the beginning of the AIDS pandemic, affective disorders (such as depressed mood) were seen in a considerable number of HIV-1-infected individuals. These disorders were a result of the poor physical condition of the patients, brain involvement by the virus (e.g. encephalopathy) or a reaction to disadvantageous livin...

journal_title：CNS drugs

authors： Arendt G

更新日期：2006-01-01 00:00:00

abstract：:Assessing the risk of stroke in persons with migraine is complicated by the intricate relationship between these two conditions. Both migraine and stroke are common and co-morbidity may, in some cases, be coincidental. Given the overlap of clinical symptoms in stroke and migraine, each condition may also mimic the oth...

journal_title：CNS drugs

authors： Tietjen GE

更新日期：2005-01-01 00:00:00

abstract：:Numerous in vitro and in vivo experimental animal studies have demonstrated that gangliosides, particularly GMI ganglioside (siagoside), may stimulate or accelerate the repair of peripheral and central nervous system neurons after various types of damage. Clinical studies of GMl in peripheral neuropathies and stroke, ...

journal_title：CNS drugs

authors： Schneider JS

更新日期：1994-03-01 00:00:00

abstract：:Multiple sclerosis (MS) has a profound impact on health-related quality of life (HRQoL), a comprehensive subjective measure of the patient's health status. Assessment of HRQoL informs on the potential advantages and disadvantages of disease-modifying drugs (DMDs) beyond their effects on observer-based disability and m...

journal_title：CNS drugs

authors： Jongen PJ

更新日期：2017-07-01 00:00:00

abstract：:Narcolepsy type 1 and narcolepsy type 2 are central disorders of hypersomnolence. Narcolepsy type 1 is characterized by excessive daytime sleepiness and cataplexy and is associated with hypocretin-1 deficiency. On the other hand, in narcolepsy type 2, cerebrospinal fluid hypocretin-1 levels are normal and cataplexy ab...

journal_title：CNS drugs

authors： Barateau L,Lopez R,Dauvilliers Y

更新日期：2016-05-01 00:00:00

abstract：:Lacosamide (Vimpat(®)) is a functionalized amino acid available orally (as a syrup or tablet) and as an intravenous infusion. It is believed to exert its antiepileptic effect by selectively enhancing the slow inactivation of voltage-gated sodium channels. Lacosamide is approved in several countries worldwide as an adj...

journal_title：CNS drugs

authors： Hoy SM

更新日期：2013-12-01 00:00:00

abstract：BACKGROUND:No head-to-head clinical trials have been published comparing guanfacine extended release (GXR) and atomoxetine (ATX): two nonstimulants approved for the treatment of attention-deficit/hyperactivity disorder (ADHD). However, other study designs or methods could be used to indirectly compare these two medicat...

journal_title：CNS drugs

authors： Sikirica V,Findling RL,Signorovitch J,Erder MH,Dammerman R,Hodgkins P,Lu M,Xie J,Wu EQ

更新日期：2013-11-01 00:00:00

abstract：:There have been significant developments in the understanding of depression in children and adolescents in the past few years, including an increased recognition that significant depressive illness occurs in this patient group. Pharmacological and psychotherapeutic treatments are used to manage depression in children ...

journal_title：CNS drugs

authors： Varley CK

更新日期：2006-01-01 00:00:00

abstract：OBJECTIVE:Many authors have reported discontinuation symptoms associated with selective serotonin reuptake inhibitors (SSRIs). The aim of this study was to investigate the incidence and characteristics of the discontinuation syndrome in patients who stopped treatment with the SSRIs paroxetine and fluoxetine under the u...

journal_title：CNS drugs

authors： Bogetto F,Bellino S,Revello RB,Patria L

更新日期：2002-01-01 00:00:00

abstract：:Benzodiazepine hypnotic agents were the mainstream pharmacotherapy for insomnia from the 1960s to the 1980s, but their safety profile proved to be not quite as perfect as originally expected with regard to daytime performance and cognition, and above all the risk of dependence. These risks are substantially diminished...

journal_title：CNS drugs

authors： Lee YJ

更新日期：2004-01-01 00:00:00

abstract：BACKGROUND:Antidepressant-induced liver injury is a major concern and a liver monitoring scheme has been recommended by the European Medicines Agency for agomelatine. OBJECTIVE:The objective of this study was to assess the liver safety and identify the characteristics of patients who developed a significant increase i...

journal_title：CNS drugs

authors： Perlemuter G,Cacoub P,Valla D,Guyader D,Saba B,Batailler C,Moore K

更新日期：2016-09-01 00:00:00

abstract：:Treatment-resistant depression (TRD) presents major challenges for both patients and clinicians. There is no universally accepted definition of TRD, but results from the US National Institute of Mental Health's (NIMH) STAR*D (Sequenced Treatment Alternatives to Relieve Depression) programme indicate that after the fai...

journal_title：CNS drugs

authors： Shelton RC,Osuntokun O,Heinloth AN,Corya SA

更新日期：2010-02-01 00:00:00

abstract：:Once considered rare and resistant to treatment, obsessive-compulsive disorder (OCD) has now emerged as a common, yet often unrecognized, psychiatric condition. Treatment with selective serotonin reuptake inhibitors (SSRIs) is effective in 40-60% of patients with OCD. Management of the remaining 40-60% of patients wit...

journal_title：CNS drugs

authors： Abudy A,Juven-Wetzler A,Zohar J

更新日期：2011-07-01 00:00:00

abstract：BACKGROUND:Valproate is a first-line antiepileptic agent and is also used in the treatment of bipolar disorder and migraine. It is a known human teratogen. The objective of the study was to evaluate the teratogenic risk of valproate. METHODS:All callers who contacted the Israeli Teratology Information Service (TIS) be...

journal_title：CNS drugs

authors： Diav-Citrin O,Shechtman S,Bar-Oz B,Cantrell D,Arnon J,Ornoy A

更新日期：2008-01-01 00:00:00

abstract：:The pervasive and devastating nature of substance use disorders underlies the need for the continued development of novel pharmacotherapies. We now know that glia play a much greater role in neuronal processes than once believed.  The various types of glial cells (e.g., astrocytes, microglial, oligodendrocytes) partic...

journal_title：CNS drugs

authors： Jones JD

更新日期：2020-07-01 00:00:00

abstract：BACKGROUND:The molecules that provide access to activated T cells in the CNS, including chemokines, have been considered to be a crucial step in the pathogenesis of multiple sclerosis (MS). AIMS:In this study, we investigated serial serum chemokine levels in patients with relapsing-remitting MS over 1 year and the ass...

journal_title：CNS drugs

authors： Comini-Frota ER,Teixeira AL,Angelo JP,Andrade MV,Brum DG,Kaimen-Maciel DR,Foss NT,Donadi EA

更新日期：2011-11-01 00:00:00

abstract：OBJECTIVES:Atomoxetine is commonly used to treat attention-deficit hyperactivity disorder (ADHD) in children with a broad range of cognitive abilities. We examined the association between level of cognitive functioning as determined by IQ and clinical response during treatment with atomoxetine. METHODS:The records of ...

journal_title：CNS drugs

authors： Mazzone L,Reale L,Mannino V,Cocuzza M,Vitiello B

更新日期：2011-06-01 00:00:00

abstract：:Oral fingolimod (Gilenya™), a sphingosine 1-phosphate (S1P) receptor agonist, is the first oral agent and the first in a novel class of disease-modifying therapies (DMTs) to be approved for use in the US for the treatment of relapsing forms of multiple sclerosis (MS). In the EU, fingolimod is approved for use as a sin...

journal_title：CNS drugs

authors： Scott LJ

更新日期：2011-08-01 00:00:00

abstract：:This review focuses on current information about luteal phase administration (i.e. typically for the last 2 weeks of the menstrual cycle) of pharmacological agents for the treatment of premenstrual dysphoric disorder (PMDD). Compared with continuous administration, a luteal phase administration regimen reduces the exp...

journal_title：CNS drugs

authors： Freeman EW

更新日期：2004-01-01 00:00:00

abstract：INTRODUCTION AND OBJECTIVE:Haemorrheological parameters and endothelial function are known to be altered in vascular diseases, including stroke. Treatment with HMG-CoA reductase inhibitors ('statins') improves cerebrovascular (and cardiovascular) morbidity and mortality in patients with atherosclerosis; the beneficial ...

journal_title：CNS drugs

authors： Szapary L,Horvath B,Marton Z,Alexy T,Kesmarky G,Habon T,Szots M,Koltai K,Juricskay I,Czopf J,Toth K

更新日期：2004-01-01 00:00:00

abstract：:The development of an intervention to slow or halt disease progression remains the greatest unmet therapeutic need in Parkinson's disease. Given the number of failures of various novel interventions in disease-modifying clinical trials in combination with the ever-increasing costs and lengthy processes for drug develo...

journal_title：CNS drugs

authors： Athauda D,Foltynie T

更新日期：2018-08-01 00:00:00

abstract：:Friedreich ataxia (FA) is a progressive genetic neurological disorder associated with degeneration of the dorsal columns, spinocerebellar tracts and other regions of the nervous system. The disorder results from mutations in the gene referred to as FXN. Almost all mutations are expansions of an intronic GAA repeat in ...

journal_title：CNS drugs

authors： Tsou AY,Friedman LS,Wilson RB,Lynch DR

更新日期：2009-01-01 00:00:00

abstract：:Spinal cord injury (SCI) has a number of severe and disabling consequences, including chronic pain, and around 40% of patients develop persistent neuropathic pain. Pain following SCI has a detrimental impact on the patient's quality of life and is a major specific healthcare problem in its own right. Thus far, there i...

journal_title：CNS drugs

authors： Baastrup C,Finnerup NB

更新日期：2008-01-01 00:00:00

abstract：:This article reviews the conceptual progression in the pharmacological therapy of malignant astrocytoma (MA) over the past decade, and its future trends. It is a selective rather than an exhaustive inventory of literature citations. The experience of the Brain Tumour Cooperative Group (BTCG) and earlier phase III tria...

journal_title：CNS drugs

authors： Jennings MT,Iyengar S

更新日期：2001-01-01 00:00:00

abstract：:▴ Ziprasidone is a novel antipsychotic drug. It has high affinity for serotonin 5-HT(2) and dopamine D(2) receptors in vitro, with an 11-fold higher affinity for 5-HT(2) than for D(2) receptors, suggestive of a low potential for inducing motor disturbance [including extrapyramidal symptoms (EPS)].▴ The effects of zipr...

journal_title：CNS drugs

authors： Davis R,Markham A

更新日期：1997-08-01 00:00:00

abstract：:The eating disorders anorexia nervosa and bulimia nervosa present with comorbidity in a number of important areas, including depression, bipolar disorder, anxiety disorders (obsessive-compulsive disorder, panic disorder, social anxiety disorder and other phobias, and post-traumatic stress disorder) and substance abuse...

journal_title：CNS drugs

authors： Woodside BD,Staab R

更新日期：2006-01-01 00:00:00

abstract：:The anilidopiperidine opioid remifentanil has pharmacodynamic properties similar to all opioids; however, its pharmacokinetic characteristics are unique. Favourable pharmacokinetic properties, minimally altered by extremes of age or renal or hepatic dysfunction, enable easy titration and rapid dissipation of clinical ...

journal_title：CNS drugs

authors： Beers R,Camporesi E

更新日期：2004-01-01 00:00:00

abstract：:Disability, characterised by the loss of ability to perform activities of daily living (ADL), is a defining feature of dementia that results in growing caregiver burden and the eventual need for alternative care or nursing home placement. Functional decline in patients with dementia can also result from causes other t...

journal_title：CNS drugs

authors： Desai AK,Grossberg GT,Sheth DN

更新日期：2004-01-01 00:00:00